FOLH1 and adenocarcinoma: Indeed, specific PET tracers can noninvasively characterize adenocarcinoma by targeting the prostate-specific membrane antigen (PSMA; e.g.,68Ga-PSMA-617) or neuroendocrine CRPC via the somatostatin receptor (68Ga-DOTATATE), offering new tools for in vivo visualization of IIH (13).